Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-18T12:54:39.318Z Has data issue: false hasContentIssue false
  • English
  • Français

Issues in pharmacoeconomic studies with psychotropics: Some practical considerations

Published online by Cambridge University Press:  16 April 2020

G Simeon
G Simeon*
Affiliation:
Ciba-Geigy, Pharma Division, 147636 Klybeckstrasse, 4002Basel, Switzerland
Get access

Summary

The assessment of quality of life (QoL) and economic outcomes of psychotropic medications are closely related. Both costs and QoL are important in establishing the value of new and existing drugs in order to assist patients, physicians, payors of health care, and society to make optimal decisions. These parameters may be combined, as in cost-utility analyses, or analysed separately. Although not a true reflection of normal practice, clinical trials are most often the setting for measurement of these parameters. The viability of such analyses, which often necessitate the inclusion of active comparators and additional work measuring costs and QoL, within the context of controlled studies must be established early on in the development process. If ‘registration oriented’ trials are inappropriate, alternative strategies must be pursued.

Keywords

pharmacoeconomicsquality of lifetrial design
Type
Research Article
Information
European Psychiatry , Volume 12 , Issue S3 , 1997 , pp. 275s - 278s
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anton, SFRevicki, DAThe use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: A cost-effectiveness study of nefazodone Psychopharmacol Bull 31 2 1995 249–258Google ScholarPubMed
Bentkover, JDFeighner, JPCost analysis of paroxetine versus imipramine in major depression PharmacoEconomics 8 3 1995 223–232CrossRefGoogle ScholarPubMed
Cohen, LJPharmacoeconomic issues in the treatment of depression. Formulary 1995; 30: S20S25Google ScholarPubMed
Davis, LMDrummond, MFAssessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42CrossRefGoogle Scholar
Hatziandrou, EJBrown, RERevicki, DAet al.Cost Utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin PharmacoEconomics 531994 249–264CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.